Clinical trials
1 active trial in Russia
Recruiting, about to start, or running now.
- Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab NCT07041268
Updated
Reviewed by Chandani Patel
Russia Over-the-Counter CGM Market Industry Trends and Forecast to 2034: Segmented by (Product, User, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$44.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.3 Mn | — | — |
| 2025 (base) | $3.1 Mn | +$0.8 Mn | — |
| 2026 (forecast) | $4.2 Mn | +$1.1 Mn | +35.4% |
| 2027 (forecast) | $5.7 Mn | +$1.5 Mn | +83.3% |
| 2028 (forecast) | $7.7 Mn | +$2.0 Mn | +148.2% |
| 2029 (forecast) | $10.5 Mn | +$2.7 Mn | +236.1% |
| 2030 (forecast) | $14.2 Mn | +$3.7 Mn | +355.1% |
| 2031 (forecast) | $19.2 Mn | +$5.0 Mn | +516.2% |
| 2032 (forecast) | $26.0 Mn | +$6.8 Mn | +734.3% |
| 2033 (forecast) | $35.2 Mn | +$9.2 Mn | +1,029.7% |
| 2034 (forecast) | $47.7 Mn | +$12.5 Mn | +1,429.6% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $3.1 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $47.7 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 35.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, user and end user (see all) |
| Key players | Dexcom, Inc., Abbott Laboratories, Levels Health, Nutrisense, Signos (see all) |
| Regulator in Russia | RoszdravnadzorSource: Roszdravnadzor. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Over-the-counter continuous glucose monitors are sensors sold without a prescription to adults who want to see how food and activity affect their blood sugar.
Key segments of the over-the-Counter CGM market include product (Biosensors and Mobile Apps and Subscriptions) and user (Non-Insulin Type 2 Diabetes, Prediabetes and Wellness Users).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the over-the-Counter CGM market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the over-the-Counter CGM market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the over-the-Counter CGM market. Long-term safety data and lifestyle support are still needed for many patients.
The over-the-Counter CGM market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices are registered by Roszdravnadzor, the federal health care regulator.[1] Compulsory medical insurance (OMS) pays for a guaranteed package of free care, through the Federal Compulsory Medical Insurance Fund.[2] Diabetes (adults): 8.1% of adults in 2022, the latest WHO figure for Russia.[3]
[1] Roszdravnadzor. Checked 14 Nov 2026.
[2] Federal Compulsory Medical Insurance Fund. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 22 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how over-the-Counter CGM products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Russia.
What doctors and scientists are doing in Over-the-Counter CGM right now, from free public sources.
1 active trial in Russia
Recruiting, about to start, or running now.
8.1 % of adults
Diabetes (adults), Russia, 2022 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 21 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 22 Nov 2026.
From our blog
Russia
Russia
Russia
Russia
Russia
Russia
OTC & Nutraceuticals · Russia
Pharmaceuticals · Russia
OTC & Nutraceuticals · Russia
Healthcare Services · Russia
Digital Health · Russia
Pharmaceuticals · Russia